Semaglutide Dose Options Reviewed

Curious about semaglutide dose options? Learn how dosing works and what to expect when starting this GLP-1 medication.

Key takeaways
  • Semaglutide is administered as a once-weekly injection, with doses starting low and increasing gradually over time.
  • FDA-approved doses vary depending on the product: Ozempic® (for type 2 diabetes) and Wegovy® (for chronic weight management with qualifying conditions).
  • Licensed healthcare providers determine the appropriate dose of semaglutide based on your medical history, response to treatment, and treatment goals.
  • Eden connects individuals with independent, licensed providers who may prescribe semaglutide through state-licensed pharmacies if medically appropriate.

If you’re exploring GLP-1 medications, you may be wondering what semaglutide dose options are available and how they’re prescribed. Whether you're considering treatment for metabolic health or chronic weight management, understanding how dosing works is key to setting realistic expectations.

This article explains how semaglutide dosing is typically structured, how it may be adjusted over time, and what to expect during the first few months. We also explain how Eden fits into the process by helping you connect with independent, licensed healthcare providers who can evaluate your needs.

Is GLP-1 Treatments right for you?

Is GLP-1 Treatments right for you?

Get started

What Is Semaglutide?

Semaglutide is a GLP-1 receptor agonist, a class of medications that mimics a hormone involved in appetite regulation, digestion, and insulin release. It is currently available in the U.S. under several FDA-approved brand names:

  • Ozempic® – approved for managing type 2 diabetes
  • Wegovy® – approved for chronic weight management in adults with qualifying conditions
  • Rybelsus® – an oral semaglutide approved for type 2 diabetes

Each product has its own approved semaglutide dose schedule and use case.

{{primary-cta}}

How Semaglutide Dosing Works

Semaglutide is typically administered once per week via subcutaneous injection. To possibly reduce side effects and improve tolerability, licensed providers often start patients on a low dose and gradually increase it over several weeks.

Why is dosing gradual?

The idea is that this step-up approach gives your body time to adjust and may help reduce side effects such as nausea, bloating, or fatigue. The dose escalation schedule is individualized, based on tolerance and clinical goals.

Semaglutide Dose Options by Brand

Here’s a breakdown of FDA-approved semaglutide dose schedules for Wegovy® and Ozempic®:

Wegovy® (for chronic weight management)

Timeframe Semaglutide Dose
Weeks 1–4 0.25 mg once weekly
Weeks 5–8 0.5 mg once weekly
Weeks 9–12 1.0 mg once weekly
Weeks 13–16 1.7 mg once weekly
Week 17+ 2.4 mg once weekly (maintenance dose)

Wegovy® is approved for use in adults with:

  • A BMI of 30 or greater, or
  • A BMI of 27 or greater with at least one weight-related condition, such as high blood pressure or elevated cholesterol

Ozempic® (for type 2 diabetes management)

Timeframe Semaglutide Dose
Weeks 1–4 0.25 mg once weekly
Weeks 5+ 0.5 mg once weekly
Optional Step 1.0 mg or 2.0 mg weekly, depending on clinical response

Ozempic® is not FDA-approved for weight loss in individuals without type 2 diabetes. However, weight change may be observed as a secondary effect in some patients.

{{primary-cta}}

How Do Providers Choose the Right Semaglutide Dose?

Licensed providers determine the appropriate semaglutide dose based on several factors, including:

  • Current BMI and health status
  • Presence of type 2 diabetes or other metabolic conditions
  • History of medication tolerance
  • Side effect profile
  • Individual goals and response to therapy

Dosing is not one-size-fits-all. That’s why it’s important to consult with a licensed healthcare provider who can personalize your treatment approach.

What Happens If You Miss a Dose?

If you miss a dose of semaglutide, most product labels (such as those for Wegovy® and Ozempic®) allow you to take the missed dose within 5 days of the scheduled injection. After that window, you should skip the dose and resume your normal schedule.

Important: Always confirm your instructions with your licensed provider, as guidance may vary based on your dose level and medical history.

Common Side Effects by Dose Level

Side effects may vary by dose and individual tolerance. These are typically more noticeable during dose escalation phases.

Common side effects:

  • Nausea
  • Constipation or diarrhea
  • Abdominal discomfort
  • Fatigue

In clinical trials like STEP 1, side effects tended to appear most often in the first 8–12 weeks and decreased over time for many participants. Your provider may recommend supportive strategies, which may help manage side effects during dose adjustments.

{{primary-cta}}

Eden’s Role in Semaglutide Access

Eden is neither a pharmacy nor a healthcare provider. Instead, Eden is a digital health platform that connects individuals with independent, licensed healthcare providers who evaluate whether a semaglutide-based treatment is appropriate.

If treatment is prescribed, medications are filled through state-licensed pharmacies and shipped directly to your door. Eden does not create, compound, or manufacture medications.

Our goal is to provide safe, seamless access to care without the guesswork.

Conclusion

Understanding your semaglutide dose options can help set expectations and ensure a smoother start. Whether your treatment is focused on managing weight or improving metabolic health, dosing is a key part of the journey, and it's designed to be gradual, safe, and tailored to your needs.

If you're ready to learn whether semaglutide may be right for you, Eden can help connect you with a n independent, licensed provider for personalized care.

Ready to explore your options? Start your consultation with a licensed provider and find out if semaglutide is the right fit for your health goals.

Disclaimer: The FDA does not approve compounded medications for safety, quality, or manufacturing. Prescriptions and a medical evaluation are required for certain products. The information provided on this blog is for general informational purposes only. It is not intended as a substitute for professional advice from a qualified healthcare professional and should not be relied upon as personal health advice. The information contained in this blog is not meant to diagnose, treat, cure, or prevent any disease. Readers are advised to consult with a qualified healthcare professional for any medical concerns, including side effects. Use of this blog's information is at your own risk. The blog owner is not responsible for any adverse effects or consequences resulting from the use of any suggestions or information provided in this blog.

Eden is not a medical provider or a pharmacy. Eden connects individuals with independent licensed healthcare providers who independently evaluate each patient to determine whether a prescription treatment program is appropriate. All prescriptions are written at the sole discretion of the licensed provider. Medications are filled by independent, state-licensed pharmacies. Eden does not manufacture, own, or dispense any medications. Please consult a licensed healthcare provider before making any medical decisions.

Frequently asked questions

GLP-1 Treatments
Personalized doctor-led plans
As low as $276/mo*
Get started
Important safety information
Verified Customer
"I had an incredible experience, and the support that Eden provides is 10/10"
Kerstin
Verified Customer
“I had so many questions in the beginning, and both the doctor and customer support were so patient and thorough.”
Lane L.

Is GLP-1 Treatments right for you?

Is GLP-1 Treatments right for you?

Get started

References

Wilding, J. P., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/nejmoa2032183